Nefopam Biogaran (Nefopam)

Nefopam acts by inhibiting the reuptake of norepinephrine, serotonin and dopamine, while also blocking sodium channels and modulating calcium influx in neurons. These combined actions reduce neuronal excitability and produce a central analgesic effect without engaging opioid pathways.

The specific dose and dosing schedule of Nefopam Biogaran are determined by the prescribing clinician based on the patient’s condition, severity of pain, and response to therapy. Healthcare professionals should follow local prescribing guidelines and adjust as needed.

Safety data for Nefopam Biogaran during pregnancy and lactation are limited. It should only be used when the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To order Nefopam Biogaran, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and import documentation.

Compared with opioid analgesics, nefopam provides effective pain relief without the risk of respiratory depression or dependence. Unlike NSAIDs, it does not inhibit cyclo‑oxygenase enzymes, so it carries a lower risk of gastrointestinal bleeding but may have central nervous system side effects such as dizziness or tachycardia.

Store Nefopam Biogaran at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure that vials or ampoules are not damaged before use.

Nefopam Biogaran is administered by a healthcare professional via intramuscular or intravenous injection. The route, injection site and rate of administration are selected according to the clinical situation and the prescribing information.

Serious adverse reactions include tachycardia, severe hypotension and rare seizures. Patients should be monitored for rapid heart rate, sudden drops in blood pressure, or any signs of convulsive activity, and medical attention should be sought immediately if these occur.

Nefopam Biogaran should be avoided in patients with a known hypersensitivity to nefopam, those taking monoamine oxidase inhibitors, or individuals with uncontrolled epilepsy. Caution is also advised for patients with significant cardiovascular disease, severe renal or hepatic impairment, and pregnant or breastfeeding women unless clearly indicated.